RightFit
Not yet recruitingNot applicable

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 14 days
  • Procedures mentioned: Heart tracing (ECG), Wearing a device

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds."
  • "Each participant will receive usual care plus two wearable patch-based cardiac monitoring devices."
  • "Mobile cardiac telemetry will be performed using the FDA-cleared Preventice BodyGuardian Mini Plus ambulatory ECG monitor to collect continuous heart rhythm data."
  • "A wearable cardiac monitor patch will also be used to record heart sounds using an accelerometer."
  • "Participants will be screened for eligibility and, after informed consent, will be fitted with the wearable devices."
  • "Baseline data will be collected through electronic medical record review, including demographics, medical history, laboratory values, EKG results, echocardiogram results, medications, cancer treatment information, and clinical events."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This small study tests whether two wearable heart patches can help find signs of heart damage during cancer treatment. It is for adults with breast cancer, blood cancers such as leukemia or lymphoma, or multiple myeloma. Participants get their usual care and wear patches that track heart rhythms and record heart sounds.

This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment. Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers. Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have breast cancer, a blood cancer such as leukemia or lymphoma, or multiple myeloma.
  • Be at least 18 years old.
  • Be able to understand the study and willing to sign a consent form.

Who can't join

  • Have a known allergy to the sticky patches used for wearable heart monitoring.
  • Be younger than 18.
  • Have problems with thinking or understanding.
  • Be a prisoner.
  • Be on active duty in the military.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma * At least 18 years of age * Capable of understanding and willing to sign a consent form for this study Exclusion Criteria: * Known allergy to adhesive patches used for ambulatory EKG monitoring * Children * Cognitively challenged individuals * Prisoners * Active service military personnel

Study sites (1)

MN